Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

67.00 -2.12 (-3.06%)
Streaming Delayed Price Updated: 1:35 PM EDT, May 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
News headline image
Masters In Trading - Saturday, June 22 ↗
In this video, I discuss a stock that is expected to see major upside, and I take a closer look at my portfolio. 
Via Talk Markets
News headline image
BridgeBio Pharma Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
Why BridgeBio Pharma Stock Is Trading Lower Tuesday ↗
BridgeBio Pharma, Inc. 
Via Benzinga
News headline image
Recap: BridgeBio Pharma Q4 Earnings ↗
 
Via Benzinga
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma to Participate in the 45th Annual Goldman Sachs Global Healthcare Conference
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma, Inc. (BBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
The 3 Best Biotech Stocks to Buy in June 2024 ↗
Explore the best biotech stocks to buy in June 2024, with insights on Protagonist, BridgeBio and Intellia. 
Via InvestorPlace
News headline image
BridgeBio Pharma Shares One Year Data From Dwarfism Candidate ↗
BridgeBio Pharma revealed results from the PROPEL 2 Phase 2 trial of infigratinib in children with achondroplasia. Key data shows sustained increases in height velocity and improved body... 
Via Benzinga
News headline image
BridgeBio Stock Makes A Bullish Move On Dwarfism Treatment Results ↗
BridgeBio stock rallies on upbeat study results of a drug for a genetic disease that affects the limbs and spine. 
Via Investor's Business Daily
News headline image
BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
7 Biotech Stocks to Put on Your Breakthrough Radar ↗
Although biotech stocks can present volatility risks due to its feast-or-famine nature, their narrative offers permanent relevance. 
Via InvestorPlace
News headline image
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BBIO Stock Earnings: BridgeBio Pharma Beats EPS, Beats Revenue for Q1 2024 ↗
BBIO stock results show that BridgeBio Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
From BridgeBio Pharma, Inc.
Via GlobeNewswire
News headline image
What's Going On With BridgeBio Pharma Stock On Monday? ↗
BridgeBio Pharma partners with Bayer on acoramidis for ATTR-CM in Europe. $310 million deal, FDA application accepted. 
Via Benzinga
News headline image
BridgeBio, A Top 3% Biotech, Just Snagged A $310 Million Deal; Will Shares Break Out? ↗
BridgeBio will receive a tiered royalty on sales that begins at the low-30% range. 
Via Investor's Business Daily
News headline image
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
From BridgeBio Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.